Atherosclerosis: Lessons Learned and Concepts Challenged
Organizer(s): Laura F. Michael, Gerard Pasterkamp and Sekar KathiresanDate: February 04 - 08, 2018
Location: Sagebrush Inn & Suites, Taos, NM, USA
Atherosclerosis is a chronic, systemic disease process whereby fatty deposits, inflammation and fibrosis accumulate in arterial vessel walls. Organ systems, including heart, brain and kidneys, as well as extremities, can be damaged, leading to atherosclerosis-driven clinical outcomes. According to the American Heart Association, 15.5 million Americans have coronary heart disease, of which 7.6 million experienced myocardial infarction. These statistics are reflective of global incidence. Treatment of atherosclerosis often begins with robust cholesterol-lowering treatments, yet many patients continue to experience cardiovascular events. Recent attempts to provide cardiovascular protection to such patients have included anti-inflammatory and HDL-raising therapeutic approaches that have yielded little benefit. Building knowledge of atherosclerosis disease etiology, defining unique attributes of patient differences as simple as sex or genetic inheritance, and using technology to identify patients with early disease is foundational for the scientific community to develop urgently needed therapeutics. The current concept of acute coronary syndrome (“the vulnerable plaque”) and widely applied animal models are debated because clinical presentation, underlying pathology and pathogenetic mechanisms are subject to change due to improved medical treatment. The goals of this meeting are to: 1) Challenge current dogma of atherosclerosis etiology and explore intra-organ cross-talk that may underlie disease evolution; 2) Consider emerging risk factors and their origins as intervention targets; and 3) Explore cutting-edge technologies to discover new therapeutic targets and approaches for drug development. By bringing together scientists from preclinical to clinical settings and from industry to academic institutions, this conference will nurture discussions to translate breakthrough discoveries into therapeutics.
Scholarship Deadline: October 5 2017
Discounted Abstract Deadline: October 5 2017
Abstract Deadline: November 7 2017
Discounted Registration Deadline: December 7 2017
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Regeneron Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Heart, Lung, and Blood Institute (NHLBI)
Grant No. 1 R13 HL140612-01
Funding for this conference was made possible (in part) by 1 R13 HL140612-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.